alks 2680
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Mar 28, 2024 (NCT06358950)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Orexin receptor 2AGONIST
HCRTR2 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06843590 | Phase 2 | Apr 30, 2025 | Alkermes |
| NCT06767683 | Phase 2/Phase 3 (Phase 3) | Jan 31, 2025 | Alkermes |
| NCT06555783 | Phase 2 | Jul 26, 2024 | Alkermes |
| NCT06358950 | Phase 2 | Mar 28, 2024 | Alkermes |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alkermes | For profit | 4 | 4 | 2 | 2024 |
1 organizations
Page 1 / 1